Bullish case
$80.00 to $100.20
More likely if Veracyte shows accelerating revenue growth, successful Prosigna breast test adoption, improving reimbursement coverage, and price reclaims resistance with sustained volume.
Veracyte, Inc. research snapshot
VCYT AI Stock Analysis
VCYT AI stock analysis currently reads Veracyte as a precision oncology diagnostics company with an improving financial profile and strong recent momentum. The page uses a scenario framework, not a certain price prediction. At the July 12, 2026 cutoff, the quoted price was $59.30, market capitalization was about $4.73 billion, and the main decision point is whether growth and margin expansion can sustain the current valuation multiple. This is informational research and not investment advice.
Current price
$59.30
Market cap
$4.73 billion
AI score
58 / 100
Rating
Improving profitability, elevated valuation
Trend status
Strong uptrend near 52-week highs
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
Research quality check
- information Richness
- B-level information richness. Veracyte is a mid-cap diagnostics company with moderate analyst coverage, available SEC filings, and liquid technical data.
- bias Check
- The AI bias risk is extrapolating recent price momentum. The analysis separates quote-verified facts from forward-looking judgments.
- ai Confidence
- Medium-high data confidence
- investment Certainty
- Low to medium. The stock can be useful for research screens, but position decisions require first-party filings, live chart data, and personal risk constraints.
Quick verdict table
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Veracyte sells genomic diagnostic tests for thyroid, prostate, breast, and lung cancer using proprietary classifiers and RNA sequencing. | Medium |
| Moat | The moat is built from proprietary genomic classifiers, payer reimbursement infrastructure, and clinical validation data. Barriers are moderate. | Medium |
| Management | Management has executed well on commercial expansion and recently launched the Prosigna breast test in the US. Insider selling after the rally warrants monitoring. | Medium-low |
| Financial trend | Revenue growing around 15-20% annually. Company recently turned profitable with TTM net income of $88M. Strong cash position of $439M with minimal debt. | Medium |
| Valuation | PE of 52x TTM and 32x forward is elevated. Price/Sales of 8.4x and EV/EBITDA of 36x imply high growth expectations already priced in. | Medium-low |
| Technical trend | Strong uptrend with stock near 52-week highs. Up 119% over the past year. Use live moving averages, support, resistance, and momentum before acting. | Medium |
| Risk level | The thesis can fail if reimbursement pressure increases, competition from liquid biopsy intensifies, growth decelerates, or the multiple contracts. | Medium |
| AI confidence | Medium-high data confidence for qualitative mapping and quote math. Lower confidence for forward returns. | Medium-high data confidence |
| Investment certainty | Low to medium certainty because the page gives a framework, not a personalized buy or sell instruction. | Low to medium |
VCYT AI stock forecast
VCYT AI Stock Forecast Scenarios
The VCYT AI stock forecast uses scenario ranges around the $59.30 quote rather than a point target. The bullish case requires sustained revenue growth above 20% and margin expansion; the base case assumes mid-teens growth at current margins; the bearish case assumes growth deceleration or competitive pressure compresses the multiple.
Base case
$48.00 to $70.00
More likely if revenue grows in the mid-teens, margins expand gradually, and the stock trades around current expectations while investors wait for the next earnings update on July 30, 2026.
Bearish case
$26.00 to $42.00
More likely if these risk paths appear: reimbursement pressure intensifies, liquid biopsy competitors gain share, growth decelerates below 10%, or technical support breaks after the data cutoff.
VCYT AI technical analysis
VCYT AI Technical Analysis
VCYT AI technical analysis starts from the $59.30 quote. Because this static page does not fetch request-time chart data, moving averages and live momentum should be confirmed in a charting tool before use.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $59.30 | Current quote used for this page as of the July 12, 2026 data cutoff. |
| Near support | $50.00 to $54.00 | Estimated from the current quote and recent pullback levels. Treat as a planning zone, not a guaranteed floor. |
| Near resistance | $59.86 to $63.00 | The 52-week high of $60.91 is nearby. A close above this zone would confirm trend continuation. |
| 50-day moving average | Requires live chart confirmation | Use current chart data before acting. The page does not fetch request-time market data. |
| 200-day moving average | Requires live chart confirmation | Long-term trend confirmation should be checked against a live chart or broker data. |
| Momentum | Strong uptrend near 52-week highs | The stock has rallied 119% over the past year. Momentum is favorable but extended. |
| Volume | Below average volume snapshot | The recent volume of 659K is below the average of 1.2M, which can reduce conviction on breakout moves. |
| Volatility | High monitoring priority | Beta of 1.93 means the stock is nearly twice as volatile as the market. |
| Invalidation | Close below $50.00 | A decisive close below the support zone would weaken the short-term uptrend. |
VCYT AI trading strategy
VCYT AI Trading Strategy Framework
The VCYT AI trading strategy is a rules-based research framework. It is not personalized advice and should be paired with position sizing, stop levels, and fresh filings or news checks.
Trend-following setup
Wait for VCYT to hold above near support and push through the 52-week high resistance zone with above-average volume that confirms buyer demand.
A close below the support zone or a failed breakout above $61 should invalidate the setup.
Mean-reversion setup
If VCYT pulls back toward the $50-$54 support band without a thesis break, compare price action with the next earnings, balance sheet, and industry datapoints.
Do not average down without a predefined maximum loss and a fresh review of the business risk.
Fundamental monitor
Track the evidence that matters most for precision oncology diagnostics: revenue growth trajectory, gross margin trends, reimbursement changes, competitive positioning, and management execution.
Reduce confidence when price moves are driven by hype without matching financial evidence.
Investment research summary
Four-master Research Compression
Business essence
Veracyte sells genomic diagnostic tests that help doctors classify thyroid nodules, assess prostate cancer risk, characterize breast cancer subtypes, and detect lung cancer earlier using proprietary RNA sequencing classifiers.
Moat
The moat is built from proprietary genomic classifiers, clinical validation data that supports payer reimbursement, and an installed base of nCounter analysis systems. Barriers are moderate due to competition from liquid biopsy and sequencing advances.
Munger risk inversion
The thesis can fail if reimbursement pressure from Medicare and commercial payers intensifies, if liquid biopsy competitors like Guardant Health erode market share, or if the nCounter platform faces technology obsolescence.
Management
Management has delivered improving financial results and recently launched the Prosigna breast test commercially in the US. Insider selling following the strong rally is a factor to monitor for alignment signals.
Industry trend
Precision oncology diagnostics is a secular growth trend driven by aging populations, increasing cancer incidence, and the shift toward targeted therapies that require genomic profiling.
Valuation and margin of safety
At 52x TTM earnings and 8.4x sales, the valuation assumes sustained high growth and margin expansion. Safety margin is thin if growth decelerates or the multiple contracts.
Source-backed data
VCYT Data Table
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| VCYT price | $59.30 | Current quote snapshot cross-checked with Yahoo Finance and market scan | July 12, 2026 |
| Market capitalization | $4.73 billion, verified as $59.30 x 79.8M implied shares | financial_rigor.py market cap verification | July 12, 2026 |
| Exchange | NasdaqGM | Yahoo Finance and public quote pages | July 12, 2026 |
| Revenue (TTM) | $541.74M | Yahoo Finance statistics | July 12, 2026 |
| Net income (TTM) | $88.01M | Yahoo Finance financials | July 12, 2026 |
| Cash (MRQ) | $439.06M | Yahoo Finance balance sheet | July 12, 2026 |
| Debt/Equity | 2.93% (minimal leverage) | Yahoo Finance statistics | July 12, 2026 |
| Free cash flow (TTM) | $104.51M | Yahoo Finance statistics | July 12, 2026 |
| Financial statement depth | Public filings available; two-source statement checks not fully completed for this batch page | Research quality check | July 12, 2026 |
Frequently Asked Questions
Use Pineify AI Stock PickerBuild an AI trading strategyRun an AI stock screenerRead the NVDA AI stock analysisRead the GH AI stock analysis
This VCYT AI stock analysis page is an informational tool only. It is not investment advice, a recommendation, or a promise of future returns. Forecast scenarios are based on available data as of July 12, 2026, may be incomplete, and can be wrong if new filings, market prices, company events, or macro conditions change.
Related Tools
Trading Strategy Builder
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Try it
Stock Screener
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Try it
AI Stock Picker & Screener
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
Try it